INC Research Expands Relationships with SCRS
INC Research, a global Phase I to IV contract research organization, announced an expanded relationship with the Society for Clinical Research Sites (SCRS) to become the society’s first Circle of Sustainability Sponsor. Through this enhanced relationship, INC Research will be the first organization to support SCRS’ new member Scholarship Program as well as the first CRO to establish a Site Advocacy Group (SAG). INC Research also will continue as a Global Impact Partner and Site Appreciation Reception sponsor for all SCRS’ Site Solutions Summit events globally across 2015.
Through the expanded relationship, INC Research will be the first CRO to establish a SAG, a new concept currently in use by TransCelerate BioPharma and Eli Lilly to facilitate ongoing dialogue with clinical investigators and site professionals worldwide in an effort to improve and drive efficiencies across the clinical development process. Through this approach, INC and investigative sites globally will exchange perspectives and insights on innovative methods, tools and technologies to enhance clinical research efficiency and more closely align the work of the sites and industry across the research ecosystem.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
